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Abstract
Background: Our aim was to determine the efficacy of a trivalent inactivated split virus influenza vaccine
(TIV) against culture-confirmed influenza A and/or B in adults 18 to 64 years of age during the 2005/2006
season in the Czech Republic.
Methods: 6203 subjects were randomized to receive TIV (N = 4137) or placebo (N = 2066). The sample
size was based on an assumed attack rate of 4% which provided 90% power to reject the hypothesis that
vaccine efficacy (VE) was ≥ 45%. Cases of influenza like illness (defined as fever (oral temperature ≥37.8°C)
plus cough and/or sore throat) were identified both by active (biweekly phone contact) and passive (self
reporting) surveillance and nasal and throat swabs were collected from subjects for viral culture.
Results: TIV was well tolerated and induced a good immune response. The 2005/2006 influenza season
was exceptionally mild in the study area, as it was throughout Europe, and only 46 culture-confirmed cases
were found in the study cohort (10 influenza A and 36 influenza B). Furthermore among the B isolates, 35
were identified as B/Hong Kong 330/2001-like (B/Victoria/2/87 lineage) which is antigenically unrelated to
the vaccine B strain (B/Yamagata/16/88 lineage). The attack rate in the vaccine group (0.7%) was not
statistically significantly different from the attack rate in the placebo group (0.9%).
Conclusion: Due to the atypical nature of the influenza season during this study we were unable to assess
TIV efficacy. This experience illustrates the challenge of conducting a prospective influenza vaccine efficacy
trial during a single season when influenza attack rates and drift in circulating strains or B virus lineage
match can be difficult to estimate in advance.
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Background
Influenza is a highly contagious infectious disease result-
ing in acute respiratory illness in people of all ages.
Annual epidemics occur worldwide and cause substantial
morbidity and mortality [1,2]. Influenza poses a particu-
lar risk to the elderly and also to people suffering from
conditions such as chronic heart or pulmonary disease.
The causative agents are influenza A and influenza B
viruses and the main virulence factors are the virus surface
coat proteins hemagglutinin (HA) and neuraminidase
(NA). There are several antigenic forms of HA and NA for
influenza A which is classified into subtypes based on dif-
ferent combinations of these antigens [1,3,4]. Only a few
of these influenza A subtypes have ever been associated
with human disease and the subtypes currently in circula-
tion in human hosts are H1N1 and H3N2 [5]. The influ-
enza B virus currently belongs to two evolutionary
lineages that are distinct at the genetic and antigenic levels
and which are represented by B/Yamagata/16/88-like and
B/Victoria/2/87-like viruses that have co-circulated in the
population since the mid-1980s [5-8]. In order to evade
the host immune system, the HA and NA proteins of both
influenza A and influenza B viruses undergo continuous
mutation and by this mean evade the host immune sys-
tem. This is known as antigenic or genetic drift [1,5,9,10].
Influenza vaccination has been employed for many years
as the primary tool to prevent influenza virus infection
and its complications [2]. As recommended by the World
Health Organization (WHO), vaccines are trivalent con-
taining two influenza A strains (H1N1 and H3N2) and
one influenza B strain [1]. However, to ensure efficacy
against new drift variants the vaccine strains must be
updated on an annual basis for both the Northern and the
Southern hemisphere [11]. Based on epidemiology and
phylogenetic analysis of HA and NA sequences of the cir-
culating human strains detected though a global influenza
surveillance network, WHO recommends the three strains
that are anticipated to become dominant during the next
influenza season [11]. Although in most years the recom-
mendations accurately predict a close antigenic match
between the vaccine and circulating strains, occasionally a
predominant circulating strain turns out to be antigeni-
cally different from the corresponding vaccine strain. As
two influenza B virus lineages co-circulate, the current rec-
ommendation to include only one lineage in each year's
TIV poses a particular risk for a mismatch. Vaccine strain
mismatch can have a negative impact on vaccine efficacy
[9,10,12,13].
In this paper we describe an efficacy study conducted with
a trivalent inactivated split-virus influenza vaccine (TIV)
manufactured by GlaxoSmithKline Biologicals which has
been available since 1987 and is now used in over 100
countries [4,14,15]. As for other inactivated influenza vac-
cines, the ability of TIV to induce HA antibody levels (as
measured in hemagglutination-inhibition (HAI) assay)
that meet regulatory authority criteria has been accepted
as a surrogate marker for efficacy [4,14,15]. Recently, this
TIV vaccine was approved under the United States' accel-
erated approval regulation [4,15]. To fulfill the require-
ments of this regulation, post-approval demonstration of
clinical benefit in an adequate and well-controlled clinical
trial is required.
We designed a placebo-controlled randomized efficacy
study with a primary clinical endpoint based upon rates of
culture-confirmed influenza A and/or B disease in a target
population of healthy adults with a broad age range of 18
to 64 years. All influenza vaccine efficacy studies are sub-
ject to the unpredictable nature of the intensity of the
influenza season in which they are conducted as well as
the extent of the antigenic match between the circulating
and vaccine strains [16]. As illustrated by the outcome of
this present study, these factors can have a substantial neg-
ative impact on the assessment of vaccine efficacy.
Methods
Study design and participants
This was a randomized, double-blind, placebo-controlled
study with two groups conducted in the Czech Republic in
the 2005–2006 influenza season (Clinical trial registery:
NCT00197223). The protocol and study documents were
approved by the University Hospital Hradec Kralové Eth-
ics Committee (Sokolska, 581; 50005 Hradec Kralové,
Czech Republic). Our primary objective was to evaluate
the efficacy of TIV (2005/2006 Northern Hemisphere for-
mulation) compared with placebo in the prevention of
culture-confirmed influenza A and/or B disease in adults.
A secondary objective was to assess the efficacy of TIV to
prevent influenza like illness (ILI) during the influenza
season (which was defined as starting the first week with
two culture-confirmed cases in the study area, and ending
the last week with one culture-confirmed case in the study
area). Other secondary objectives were the assessment of
the safety and also, in a subset of subjects, the assessment
of vaccine reactogenicity and immunogenicity.
Eligible participants were self-referred clinically healthy
male or female volunteers aged between 18 and 64 years
at the time of vaccination who provided written informed
consent. A randomisation list was generated by the spon-
sor by SAS program and used to number the vaccine and
placebo treatments (which were indistinguishable in
appearance). A randomization blocking scheme (2:1) was
employed to ensure that balance between treatments was
maintained. The randomization algorithm used a mini-
mization procedure that accounted for prior influenza
vaccination, vaccine lots, and agreement to participate in
the immunogenicity/reactogenicity subset. Blinding toBMC Infectious Diseases 2009, 9:2 http://www.biomedcentral.com/1471-2334/9/2
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treatment assignment was maintained until study analy-
sis.
Vaccinations and blood sampling
Volunteers were randomized to receive one dose of TIV
(Fluarix™, a trade mark of GlaxoSmithKline group of com-
panies (GSK)) or placebo at the first study visit (study Day
0) by intramuscular injection into the non-dominant del-
toid muscle. Each 0.5-ml dose of TIV contained 15 μg each
of the hemagglutinin antigens of A/New Caledonia/20/99
(H1N1) IVR-116 virus as an A/New Caledonia/20/99-like
strain, A/New York/55/2004 (H3N2) X-157 virus as an A/
California/7/2004-like strain and B/Jiangsu/10/2003
virus as a B/Shanghai/361/2002-like strain. Placebo con-
sisted of saline for injection.
Blood samples for the assessment of immunogenicity
were obtained from the planned randomly selected subset
of volunteers just prior to vaccination and at 21 days fol-
lowing vaccination.
Case definitions
Culture-confirmed influenza (primary endpoint) was
defined as an episode of influenza like illness (ILI) occur-
ring after the administration of the study vaccine for
which a nasal and throat swab specimen yields influenza
virus A and/or B in cell culture.
ILI (secondary endpoint) was defined as fever (oral tem-
perature ≥ 37.8°C) plus cough and/or sore throat [17]. An
ILI episode was defined as the period from the first day of
ILI symptoms until the last day of ILI symptoms. A new
episode was taken into account only after the complete
resolution of the previous one. Between two ILI episodes,
there had to be at least 7 days free of any symptoms.
Follow up of subjects
From the day of vaccination all subjects were instructed to
report any ILI symptoms to the investigator via a toll free
line (passive surveillance for ILI). Active surveillance for
ILI began 2 weeks after the administration of the study
vaccine until study end (April 2006). This involved
biweekly telephone contact of the subjects to remind
them to notify the investigator at the onset of ILI symp-
toms, to identify ILI episodes which may have been unre-
ported, and to collect information on the occurrence of
medical visits and possible serious adverse events.
For each case of suspected ILI, a study nurse visited the
subject, (as far as possible on the same day) and collected
a nasal and throat swab sample (comprised of a swab of
both nasal cavities and a second swab of the throat) for
culture. Subjects were each provided with a calibrated
thermometer to measure temperature and a diary card to
record temperatures and symptoms during the influenza
like illness episode. All samples were to be obtained, if
possible, before antimicrobial/influenza antiviral therapy
was started.
A randomly selected subset of subjects were assessed for
reactogenicity using diary cards to record the presence and
intensity of injection site solicited adverse events (pain,
redness and swelling) and general solicited adverse events
(fatigue, fever, headache, muscle aches, shivering and
joint pain) experienced during the first 4 days after vacci-
nation. The diameters of any injection site redness or
swelling and daily body temperature were recorded. The
intensities of other adverse events were recorded accord-
ing to a standard 0 to 3 grade scale: "absent", "easily toler-
ated", "interferes with normal activity" and "prevents
normal activity". Data were also collected on the occur-
rence and intensity of any spontaneous unsolicited signs
or symptoms occurring within 21 days following vaccina-
tion. These diary cards were reviewed during the blood
sampling visit at Day 21. Collection of data on serious
adverse events (SAEs) began at the receipt of vaccine/pla-
cebo and continued until the end of the study.
At the end of the study the investigator made a study con-
clusion contact with all subjects.
Laboratory assays
Serum samples were stored at -20°C until blinded analy-
ses were conducted at GSK Biologicals SSW Dresden, Ger-
many. All samples were tested in a validated micro-titer
hemagglutination-inhibition test using chicken red blood
cells with the three virus strains present in the TIV used as
antigens as previously described [14]. The serum titer was
expressed as the reciprocal of the highest dilution that
showed complete inhibition of hemagglutination.
Nasal and throat swab samples were stored at 2–8°C and
transferred within 24 hours to the National Reference Lab-
oratory for Influenza (NRL, Prague, Czech Republic) for
conventional influenza virus culture in Madin Darby
Canine Kidney (MDCK) cells as described elsewhere
[18,19]. Cell culture supernatants were tested for the pres-
ence of influenza virus by hemagglutination assay with
turkey and guinea pig erythrocytes [18,19]. Hemaggluti-
nation inhibition was used to identify virus type, subtype
and drift variant [18,19]. Cell culture supernatants were
also tested by a direct immunoperoxidase assay using
anti-influenza A and anti-influenza B nucleoprotein anti-
bodies [20].
Statistical Analysis
The sample size for the primary endpoint was estimated
on the basis of an assumed influenza attack rate of 4% of
culture-confirmed influenza disease (type A and/or B)
among placebo recipients, a vaccine efficacy (VE) of 70%,BMC Infectious Diseases 2009, 9:2 http://www.biomedcentral.com/1471-2334/9/2
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and 90% power to detect vaccine efficacy with a lower
limit of the 95% CI for efficacy >45% with alpha = 0.025
(1-sided). A sample size of 5591 evaluable subjects was
required to allow the rejection of the null hypothesis that
the vaccine efficacy against culture-confirmed influenza
illness was ≤ 45%. To account for an assumed dropout
rate of 10%, we planned to enroll a minimum of 6213
subjects. According to the planned 2:1 treatment alloca-
tion approximately 4142 and 2071 subjects were to
receive TIV and placebo respectively. Based on the
assumptions of attack rate and vaccine efficacy a total of
119 culture-confirmed influenza illness episodes were
anticipated with approximately 75 episodes in the pla-
cebo group.
All data analyses were conducted according to a pre-spec-
ified plan prepared by GSK and submitted to the United
States Center for Biologics Evaluation and Research
(CBER). The vaccine efficacy against culture-confirmed
influenza A or B was defined as 1 minus the relative risk
of culture-confirmed influenza among the TIV group ver-
sus the placebo group and calculated using the classical
formula of Greenwood and Yule [21] with the 95% exact
confidence intervals (CI). The attack rate was the number
of subjects experiencing at least one episode of culture-
confirmed influenza A or B within the observation period
divided by the total number of subjects in the group. Anal-
ysis of vaccine efficacy against culture-confirmed influ-
enza A or B was performed on the total cohort for efficacy
(Figure 1) while analysis of vaccine efficacy against ILI
during the influenza season was performed on the accord-
ing to protocol (ATP) cohort for efficacy in the influenza
season (Figure 1).
Results
Baseline characteristic
The total cohort for efficacy and safety (N = 6203 subjects)
included 4137 subjects vaccinated with TIV and 2066 sub-
jects vaccinated with placebo (Figure 1). The demographic
profiles of the TIV and placebo groups in this cohort were
comparable with respect to mean age (35 ± 13 years in
both groups), gender (55.3% and 54.2% female in the TIV
and placebo groups respectively) and racial distribution
(99.8% white Caucasian in both groups). In both groups
the majority of subjects (91.5% and 91.7%) had no his-
tory of influenza vaccination within the last 3 influenza
seasons prior to enrolment.
Efficacy
During the study surveillance period (September 2005 to
April 2006), 814 episodes of ILI were evaluated with the
peak incidence occurring between November 2005 and
March 2006 (110–125 cases per month). Swab specimens
were obtained from all cases within 5 days of the onset of
ILI with the majority (742/814, 91%) collected by Day 2.
There were 46 culture-confirmed cases, 10 positive for
influenza A and 36 for influenza B (Table 1) which
occurred between January and April 2006. Seven of the
ten influenza A isolates were identified by hemagglutina-
tion inhibition titration and characterised as being anti-
genically related to the H1N1 or H3N2 vaccine strains
(Table 1). Of the 36 influenza B isolates, 35 were identi-
fied by hemagglutination inhibition titration and charac-
terized as B/Hong Kong 330/2001-like (from the B/
Victoria/2/87 lineage) which is antigenically distinct to
the B strain from the B/Yamagata/16/88 lineage contained
in the vaccine. No mixed influenza infections were identi-
fied.
As indicated in Table 2 the attack rate for culture-con-
firmed influenza A or B in the placebo group was 0.9%
which was well below the assumed attack rate of 4% on
which the sample size was based to offer 90% power to
reject the null hypothesis that VE was ≤ 45%. The attack
rate in the vaccine group (0.7%) was not statistically sig-
nificantly different so the null hypothesis could not be
rejected and the efficacy of TIV against culture-confirmed
influenza A or B could not be demonstrated (estimate of
efficacy of 22.3% with 95% CI of -49.1% to 58.5%). The
attack rate for culture-confirmed influenza A in the pla-
cebo group was very low at only 0.2%. For culture-con-
firmed influenza B (Table 2), the attack rates were 0.7% in
the placebo group and 0.5% in the vaccine group and the
lower limit of confidence for the estimate of 21.5% effi-
cacy was again a negative value (95% CI -65.9% to 61.6).
Similarly the attack rates for clinical ILI episodes during
the influenza season were not statistically different
between the vaccine (6%) and placebo (5.6%) groups and
so efficacy against clinical ILI episodes could also not be
demonstrated (Table 3).
Safety and reactogenicity
The percentage of subjects reporting an SAE was the same
(2.3%) in each group. No SAEs were reported as being
related to vaccination.
Vaccination with TIV was associated with a higher inci-
dence of solicited injection site reactions, in particular
pain at the injection site (Figure 2). The majority of these
reactions in TIV recipients were mild to moderate in inten-
sity. No events were classified as preventing daily activities
and the incidences of local redness and swelling reactions
above 50 mm diameter were low (1.7% and 2.3% respec-
tively). All resolved without sequelae. Rates of solicited
general symptoms also tended to be higher in the TIV
group (Figure 3). Fatigue was the most common solicited
general symptom reported as related to vaccination in
both groups (TIV 23.4% and placebo 15.9%). The major-
ity of reactions in TIV recipients were mild to moderate in
intensity, there were no reports of fever >39°C and theBMC Infectious Diseases 2009, 9:2 http://www.biomedcentral.com/1471-2334/9/2
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Flow of participants through the clinical trial Figure 1
Flow of participants through the clinical trial.
N = 6213
Subjects enrolled, randomised and 
vaccinated
N = 6203
Total Cohort for efficacy and safety
x10 ID numbers assigned to the 
same 4 subjects who were
vaccinated several times.
Placebo N = 2066
Total Cohort for efficacy and safety
Vaccine N = 4137
Total Cohort for efficacy and safety
Placebo N = 2003
ATP efficacy cohort Influenza Season
xProtocol violation 
(inclusion/exclusion criteria): 1
subject
xUnderlying medical condition 
forbidden by the protocol: 25 subjects
xSubjects not exposed during the 
influenza season: 37 subjects
Vaccine N = 4011
ATP efficacy cohort Influenza Season
xProtocol violation 
(inclusion/exclusion criteria): 1
subject
xUnderlying medical condition 
forbidden by the protocol: 53 subjects
xSubjects not exposed during the 
influenza season: 72 subjects
N = 960
Total Cohort Subset 
Placebo N = 320
Total Cohort Reactogenicity Subset 
Vaccine N = 640
Total Cohort Reactogenicity Subset
Placebo N = 315
ATP Cohort Immunogenicity Subset 
xUnderlying medical condition
forbidden by the protocol: 5 subjects
Vaccine N = 632
ATP Cohort Immunogenicity Subset
xUnderlying medical condition 
forbidden by the protocol: 8 subjectsBMC Infectious Diseases 2009, 9:2 http://www.biomedcentral.com/1471-2334/9/2
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highest incidence of symptoms preventing daily activities
and reported as related to vaccination was 0.5% (fatigue
and headache). Rates of spontaneously reported symp-
toms were similar in both groups both overall (TIV 11.1%
and placebo 10%) and reported as related to vaccination
(TIV 1.4% and placebo 1.6%).
Immunogenicity
Table 4 demonstrates that TIV elicited an antibody
response (as assessed by hemagglutination-inhibition)
against all three vaccine strains which exceeded the
required Committee for Medicinal Products for Human
Use (CHMP) [22] and CBER [23] criteria for seroconver-
sion and seroprotection rates.
Discussion
This paper describes the outcome of a placebo-controlled
randomized efficacy study with a trivalent inactivated
split virus influenza vaccine (TIV) in healthy adults aged
18 to 64 years. The immunogenicity of TIV was consistent
with previous studies in adults [4,15] and seroprotection
rates exceeded regulatory authority criteria. Despite this,
the vaccine efficacy was not confirmed.
Influenza vaccine efficacy in a particular region depends
on the nature of the influenza season. This can vary from
year to year and as it cannot be predicted in advance,
poses a particular challenge for the conduct of a prospec-
tive efficacy study. The optimal circumstances in which to
evaluate the efficacy of influenza vaccines are i) high viral
circulation (i.e. high attack rate) and ii) when the vaccine
strains are antigenically-matched to the circulating virus
types [16,24]. The 2005–2006 influenza season in the
Czech Republic was exceptional in that both of these fac-
tors turned out to be suboptimal for the conduct of an effi-
cacy study.
The first issue faced by the study was the very low attack
rate. The study was powered based on the assumption that
the attack rate of culture-confirmed influenza in the pla-
cebo group would be 4% while the actual attack rate dur-
ing the study was 0.9%. Literature data are limited on the
attack rates of culture-confirmed influenza cases in an
Table 1: Culture confirmed influenza episodes identified by immunoperoxidase staining or by hemagglutination inhibition titration
Total Number of Influenza A or B 
isolates
Number identified by 
immunoperoxidase typing only
Number identified by hemagglutination 
inhibition for A/H1, A/H3 and B lineage
10 Influenza A isolates 3 5 H3
A/California/7/2004-like*
2 H1
A/New Caledonia/20/1999*
and
A/Czech Republic/109/2005*
36 Influenza B isolates 1 35
B/Hong Kong 330/01-like**
* Antigenically related to the H1N1 or H3N2 vaccine strains
** Not antigenically related to the B strain from the Yamagata lineage contained in the vaccine
Table 2: Attack rates and TIV efficacy for culture confirmed influenza in adults (total cohort for efficacy)
Type of culture 
confirmed
Trivalent inactivated split virus influenza 
vaccine
N = 4137
Placebo
N = 2066
Vaccine efficacy (1-RR)
Number of cases % Attack rate Number of cases % Attack rate % 95% CI† P value †
LL UL
Any 28 0.7 18 0.9* 22.3 -49.1 58.5 0.433
Influenza A 6 0.1 4 0.2 25.1 -260.9 82.2 0.740
Influenza B 22 0.5 14 0.7 21.5 -65.9 61.6 0.481
* Sample size calculation was based on expected attack rate of at least 4% in the placebo group
† Two-sided Fisher Exact test, the 95% confidence intervals for vaccine efficacy was calculated using a conditional exact method.BMC Infectious Diseases 2009, 9:2 http://www.biomedcentral.com/1471-2334/9/2
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unvaccinated adult population and serology has been very
often used alone or combined as a diagnostic tool to con-
firm the influenza virus etiology of a clinical case. The
attack rate of 4% was hence selected as a conservative esti-
mate based upon data from randomized placebo influ-
enza vaccine studies in healthy adults with laboratory (by
serology or a mixture of serology and culture) confirmed
endpoints reviewed in the Cochrane data base [3]. These
indicated an attack rate range of 6% to 16% in the placebo
groups. More recently, prospective placebo-controlled tri-
als have reported rates of culture-confirmed cases in the
adult setting [25,26] as well as in children [27]. These
studies clearly confirmed the high year-to-year variability
of documented influenza cases.
The low number of culture-confirmed influenza cases
found during our study was unlikely to be due to inade-
quate monitoring of prospective cases, as active surveil-
lance for ILI involving contact of subjects by phone on a
biweekly basis was employed. Also, all nasal and throat
swab specimens were transported to the laboratory with
an adequate cold chain within 24 hours to avoid false cul-
ture negatives due to loss of virus viability. Furthermore,
the low attack rate observed in the study area in 2005–
2006 was confirmed by the European Influenza Surveil-
lance Scheme (EISS) [28]. Specific data for the Czech
Republic demonstrate that the weekly morbidity rates for
both acute respiratory infections [29] and for ILI [30] were
lower in the 2005/2006 influenza season compared to
both the previous 2004/2005 season and also the follow-
ing 2006/2007 season. The EISS also reported that the cir-
culation of influenza B virus in the winter 2005–2006 was
exceptional compared with European data accumulated
during the last decade, as it was the only season in which
influenza B viruses were dominant [28]. It is possible that
this may have contributed to the low attack rate of clinical
illness as influenza B is known to cause milder disease
than influenza A [28,31].
The significant impact that a lower attack rate can have on
a clinical trial to evaluate influenza vaccine efficacy has
previously been illustrated in a clinical trial conducted by
Hoberman and colleagues in young children over two
consecutive influenza seasons in Pittsburg [27]. In the first
season (1999/2000) when the attack rate for culture-con-
firmed influenza was 15.9% in the placebo group, vaccine
efficacy was estimated to be 65% (95% CI 34% to 82%)
while in the second season (2000/2001) when the attack
rate for culture-confirmed influenza was 3.3% in the pla-
cebo group, vaccine efficacy was estimated to be -7%
(95% CI -247% to 67%). A similar finding was recently
reported in a study conducted over 2 years in an adult
population in Michigan [25,26]. The attack rate of culture-
confirmed influenza in the placebo group was reported to
be 5.8%, whereas in the second year, a rate of 1.8% was
found. The VE estimates for the inactivated influenza vac-
cine were found to be 77% (37% to 92%) in year 1 and
23% (-153% to 73%) in year 2. The latter result appears to
be similar to the outcome of our study in adults where
with an attack rate in the placebo group of 0.9% for influ-
enza A and/or B cases and 0.2% for influenza A cases, the
respective estimate of efficacies were 22.3% (95% CI -
49.1% to 58.5%) and 25.1% (95% CI of -260.9% to
82.2%).
These data indicate that the possibility of a lower than pre-
dicted attack rate needs to be factored into the design of
influenza vaccine efficacy studies. Apart from increasing
the sample size or allowing for an extension of the study
over more than one influenza season, another factor to be
considered is the clinical case definition used. There is no
universally accepted clinical case definition of influenza
[32,33]. We employed a definition from the Centers for
Disease Control and Prevention (CDC) US based on the
presence of fever plus either cough or sore throat, [17].
This combination of symptoms is recognized as having a
high positive predictive value for influenza but is not very
sensitive [34]. For seasons with low attack rates it may be
Table 3: Attack rates and TIV efficacy for ILI during the influenza season* (ATP cohort for efficacy)
Trivalent inactivated split virus influenza vaccine
N = 4011
Placebo
N = 2003
Vaccine efficacy
% 95% CI† p value †
Number of 
events
Number of 
subjects 
reporting at 
least one event
% Attack rate Number of 
events
Number of 
subjects 
reporting at 
least one event
% Attack rate LL UL
254 240 6.0 120 113 5.6 -6.1 -33.8 15.5 0.642
* Influenza season starts the first week with two culture confirmed cases in the area, and closes at the end of the last week with one culture 
confirmed case in the areas.
† Two-sided Fisher Exact test, the 95% confidence intervals for vaccine efficacy was calculated using a conditional exact method.BMC Infectious Diseases 2009, 9:2 http://www.biomedcentral.com/1471-2334/9/2
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preferable to improve case capture by using less restrictive
clinical criteria particularly when culture confirmation is
being employed to confer specificity. The use of reverse
polymerase chain reaction (RT-PCR) assays techniques,
which have been shown to be more sensitive than culture,
may also improve detection of influenza virus in nasal/
throat specimens [35,36]. Serological analysis of acute
and convalescent sera, which is also often used to confirm
influenza cases, would however have specific limitations
in a vaccine efficacy study. In the vaccine group, the pres-
ence of vaccine-induced antibodies could mask differ-
ences between paired sera in levels of antibodies induced
by infection, thereby introducing a bias s in favor of the
study vaccine.
The low attack rates encountered in the adult population
during some influenza seasons may raise the question
about the need for adult vaccination. It should be kept in
mind that currently the main target populations for adult
vaccination (apart from the elderly persons, which are
outside the scope of this study) are adults who have med-
ical conditions that place them at risk for complications
from influenza and also, in order to limit influenza virus
transmission to those at risk in all age groups, health-care
personnel or caregivers [2]. As the attack rate for any com-
ing influenza season is unpredictable at the time of
annual influenza vaccination, it is not feasible to modify
vaccination routines and put susceptible people at risk.
The second issue faced by the study was a mismatch
between the dominant circulating influenza strain and the
vaccine strains. The majority of culture-confirmed cases
detected in our study were caused by an influenza B strain
that was of a different lineage to the vaccine influenza B
component which was from the B/Yamagata/16/88-line-
age. This mismatch was confirmed by the EISS who
reported that 90% of the characterized influenza B viruses
in Europe during the influenza season 2005–2006 were
similar to the B/Victoria/2/87 lineage of influenza B
viruses [28]. As a consequence, the World Health Organi-
zation (WHO) substituted a virus from the B/Victoria/2/
87 lineage in the 2006–2007 vaccine recommendations
[37].
The co-circulation of these two antigenically distinct B lin-
eages which form distinctly divergent genetic groups
based on their hemagglutinin genes where there are some
27 amino acid differences [8] has raised the question of
Incidence of solicited injection site symptoms during the first  four days following vaccination (Total cohort subset for reac- togenicity; trivalent inactivated split virus influenza (TIV) N =  640, Placebo N = 320) Figure 2
Incidence of solicited injection site symptoms during 
the first four days following vaccination (Total cohort 
subset for reactogenicity; trivalent inactivated split 
virus influenza (TIV) N = 640, Placebo N = 320).
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whether they should both be represented in the annual
influenza vaccine formulation [38]. To date, this option
has not been considered due to the constraints it would
impose on an already limited influenza antigen manufac-
turing capacity. Also, although there is no hemagglutinin
cross reactivity between the two B lineages in ferrets [7] or
unprimed children [39], serological evidence from WHO
[37] and another recent study [40] indicates that vaccine
B/Yamagata/16/88-lineage components may provide
reduced protection against the B/Victoria/2/87 lineage.
Furthermore, reassortment between the two influenza B
lineages has led to practically all B/Victoria-lineage viruses
containing a B/Yamagata-lineage neuraminidase which
may also provide some cross protection [13,38]. Other
workers have managed to demonstrate vaccine efficacy for
influenza B despite mismatch between vaccine and circu-
lating strains [13,25]. In the Michigan study, Ohmit et. al
demonstrated efficacy against influenza B during a mis-
match of B strains in the 2004/2005 season [25]. How-
ever, the attack rate for culture-confirmed influenza in the
placebo group in that study was considerably higher
(5.8%) than in the study reported here and also a greater
proportion of the influenza B isolates did match the vac-
cine strain (7 out of 18).
Although the exceptional nature of the influenza season
in which this study was conducted did not allow us to
establish the efficacy of TIV it is likely that, as demon-
strated by Ohmit et al for another inactivated vaccine [25],
TIV efficacy could be demonstrated under more typical
influenza season conditions.
Conclusion
Due to the exceptionally low attack rate during the 2005/
2006 season in the Czech Republic and the predominance
of a circulating B strain of a different lineage to the vaccine
strain, our study was unable to demonstrate the efficacy of
TIV in healthy adults. This experience illustrates the chal-
lenge of conducting an influenza vaccine efficacy trial dur-
ing one season when variations in disease attack rates and
circulating strains cannot be predicted in advance.
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IVR-116
Influenza A (H3N2)
A/New York/55/2004 (H3N2) X-
157
Influenza B
B/Jiangsu/10/2003 virus
CHMP
acceptance
criteria**
CBER
acceptance 
criteria***
TIV
N = 632
Placebo
N = 315
TIV
N = 632
Placebo
N = 315
TIV
N = 632
Placebo
N = 315
Geometric 
Mean Titer 
(GMT)
No Standard No Standard 730.5
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[10.2–13.3]
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13.5
[11.9–15.3]
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[175.7–207.9]
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[15.7–20.3]
% Sero-
conversion 
rate *
% > 40% LL of 95% CI 
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[86.6–91.5]
0.0
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protection
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